Incyte has agreed to buy Star Therapeutics subsidiary Vega Therapeutics for $1.25 billion upfront, adding a late-stage drug ...
Alongside the weight-loss result, however, were significant improvements in knee osteoarthritis pain, with an improvement of ...
Yet, while excitement around disruptive technologies remains high, bringing genuinely transformative healthcare innovations ...
Boehringer Ingelheim revealed more data behind previously reported top-line results for its dual-acting obesity drug ...
And yet, ask most HCPs whether their experience of engaging with pharma has meaningfully improved, and the answer is usually ...
An AI-designed vaccine against all variants of the coronavirus SARS-CoV-2 – designed using an AI-powered platform developed ...
Multiple sclerosis (MS) is undergoing a meaningful evolution in how it is understood, diagnosed, and managed. Advances in ...
Analysts suggested the deaths could overshadow the PFS results, and the safety trade-off may make it harder for ADC ...
Parabilis Medicines has revealed the financial details behind its recently announced IPO, hoping to raise up to $475 million ...
Final draft guidance from reimbursement authority NICE recommends Elahere (mirvetuximab soravtansine) for treating ...
Longevity start-up NewLimit has raised an eye-watering $435 million to take its lead age reprogramming candidate into human ...
AstraZeneca has presented new data from the SERENA-6 trial of camizestrant in advanced breast cancer that it hopes will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results